Please assess the completion status of the following clinical trial:

Trial Title: Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with a prior MI within the previous 2 weeks to 12 months.~2. On DAPT with low-dose aspirin (81mg od) and either prasugrel (10mg od) or ticagrelor (90mg bid) as per standard-of-care for at least 2 weeks.~3. Free from bleeding and ischemic events after the index MI event.~4. Age between 18 and 75 years old.~Exclusion criteria:~1. History of stroke, transient ischemic attack, or intracranial hemorrhage.~2. Active pathological bleeding, history of bleeding events or increased risk of bleeding.~3. Known severe hepatic impairment.~4. Age \>75 years.~5. Body weight \<60 Kg.~6. Use of strong Cytochrome P450 3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) or inducers (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin).~7. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban).~8. On treatment with any antiplatelet agent other than aspirin, prasugrel and ticagrelor in the past 14 days.~9. Creatinine clearance \<30 mL/minute.~10. Platelet count \<80x106/mL~11. Hemoglobin \<10g/dL~12. Hemodynamic instability~13. Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DAPT plus vorapaxar (Type: EXPERIMENTAL): Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
- Prasugrel/ticagrelor plus vorapaxar (Type: EXPERIMENTAL): Prasugrel or ticagrelor plus vorapaxar 2.5mg od
- DAPT (Type: ACTIVE_COMPARATOR): Aspirin in addition to prasugrel or ticagrelor

Based on this trial design, predict the completion outcome and termination type (if applicable).